TCRT

Alaunos Therapeutics, Inc.
CAPPED RATING

ZIOPHARM Oncology Inc is a biotechnology company which acquires, develops, and commercializes cancer therapies that can address unmet medical needs through synthetic biology.

Alaunos Therapeutics, Inc. (TCRT) is rated C- (1.9/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Revisions (C+); its weakest is Value (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.9 / 5.0
C-
Value
F
Factor Score 0.0 / 5.0
Growth
C+
Factor Score 2.5 / 5.0
Profitability
C-
Factor Score 1.9 / 5.0
Momentum
C+
Factor Score 2.5 / 5.0
Revisions
C+
Factor Score 2.6 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio -2.7
EV / EBITDA -1.0
Rev Growth YoY N/A
Gross Margin 0.0%
Price Return 3M -14.7%
Price Return 12M -45.5%
Catalyst Signal 0.00
Market Cap $6.9M
TTM Revenue $3.0K
Price / Sales 2.3K
ROE -185.9%

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-11-15 F (0.0) C+ (2.5) C- (1.9) C+ (2.5) C+ (2.6) C- (1.9)
2026-11-08 F (0.0) C+ (2.5) C- (1.9) D+ (1.5) C+ (2.6) D+ (1.7)
2026-11-01 F (0.0) C+ (2.5) C- (1.9) D+ (1.8) C+ (2.7) D+ (1.8)
2026-10-25 F (0.0) C+ (2.5) C- (1.9) C- (1.9) C+ (2.6) D+ (1.8)
2026-10-18 F (0.0) C+ (2.5) C- (1.9) C (2.3) C+ (2.6) C- (1.9)
Page 1 of 4